These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 7530943)
21. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Lepor H Urol Clin North Am; 1990 Aug; 17(3):651-9. PubMed ID: 1695785 [TBL] [Abstract][Full Text] [Related]
22. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case]. Gotoh M Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373 [TBL] [Abstract][Full Text] [Related]
23. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. DiSantostefano RL; Biddle AK; Lavelle JP BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339 [TBL] [Abstract][Full Text] [Related]
24. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Miner M; Rosenberg MT; Perelman MA Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576 [TBL] [Abstract][Full Text] [Related]
25. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690 [TBL] [Abstract][Full Text] [Related]
26. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. Shapiro E Urol Clin North Am; 1990 Aug; 17(3):487-93. PubMed ID: 1695777 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia. Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705 [TBL] [Abstract][Full Text] [Related]
35. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065 [TBL] [Abstract][Full Text] [Related]
36. Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? De Mey C Eur Urol; 2000; 38 Suppl 1():25-39. PubMed ID: 11111206 [TBL] [Abstract][Full Text] [Related]
37. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia]. Kawabe K Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083 [TBL] [Abstract][Full Text] [Related]
38. What's best for your patient with BPH? Neal RH; Keister D J Fam Pract; 2009 May; 58(5):241-7. PubMed ID: 19442387 [TBL] [Abstract][Full Text] [Related]
39. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281 [TBL] [Abstract][Full Text] [Related]
40. [Novel therapeutics strategies in benign hypertrophy of prostate management]. Roumeguère T Rev Med Brux; 2005 Sep; 26(4):S407-11. PubMed ID: 16240894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]